Description
PrymaLab · Research Use Only
KLOW Blend 80MG
KPV + BPC-157 + TB-500 + GHK-Cu · four peptides · 80mg total
KLOW peptide is a lyophilized four-component research vial containing KPV, BPC-157, TB-500 and GHK-Cu at 80mg total. It is the three-peptide GLOW composition with KPV added, which brings NF-κB suppression alongside vascular signalling, actin dynamics and copper-dependent matrix synthesis.
Specification Table
| Property | Value |
|---|---|
| Product format | Lyophilized powder, single vial |
| Total peptide content | 80 mg |
| Component 1 | KPV (Lys-Pro-Val) |
| Component 2 | BPC-157 |
| Component 3 | TB-500 (thymosin β4) |
| Component 4 | GHK-Cu |
| Relationship to GLOW | GLOW composition plus KPV |
| Component ratio | Not published on the product record |
| CAS, GHK-Cu | 89030-95-5 |
| CAS, BPC-157 | 137525-51-0 |
| CAS, TB-500 / thymosin β4 | 77591-33-4 |
| CAS, KPV | 67727-97-3 |
| MW, GHK-Cu | 401.91 g/mol |
| MW, BPC-157 | 1419.55 g/mol |
| MW, thymosin β4 | 4963.55 g/mol |
| MW, KPV | 342.43 g/mol |
| Sequence, KPV | Lys-Pro-Val |
| Target, KPV | NF-κB signalling, following PepT1-mediated uptake |
| Target, BPC-157 | VEGFR2, with downstream Akt and eNOS activation |
| Target, TB-500 | Monomeric globular actin, via the LKKTETQ motif |
| Target, GHK-Cu | Copper(II) coordination and fibroblast collagen synthesis |
| Appearance | Blue to blue-violet lyophilized cake |
| Purity | Per lot-specific certificate of analysis |
| Solubility | Soluble in bacteriostatic and sterile water |
| Storage, lyophilized | -20°C, protected from light and moisture |
| Storage, reconstituted | 2-8°C, protected from light |
| Reconstituted stability | Not established for this four-component mixture |
| Regulatory status | No approved human or veterinary formulation for any component |
What Does KPV Add to the GLOW Composition?
KLOW peptide is the GLOW composition with a fourth peptide, and understanding what that fourth peptide contributes is the clearest way to understand the product.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, residues 11 through 13, and it is by some distance the smallest component here at 342.43 daltons. Dalmasso and colleagues characterised its uptake through PepT1, the di- and tripeptide transporter, and reported reduced NF-κB activation downstream in intestinal epithelial and Jurkat cell lines (Dalmasso et al., 2008).
NF-κB is the transcription factor governing much of the inflammatory gene programme. Suppressing it is mechanistically distinct from anything the other three components do, and it is the one arm of this blend aimed at restraining a process rather than driving one.
That gives the four-component logic its shape: build matrix through GHK-Cu, support vasculature through BPC-157, enable cell migration through thymosin β4, restrain inflammatory signalling through KPV. Four processes that genuinely operate together in tissue.
What the logic does not establish is that combining four compounds produces coordinated action across four processes. Each was characterised alone, in its own system, at concentrations chosen for that system.
How Wide Is the Molar Spread Across Four Components?
For KLOW peptide the spread is wider than for any other product in this catalogue, and it is the single most important practical fact about the vial.
The molecular weights run from 342.43 for KPV to 4963.55 for thymosin β4. That is a factor of 14.5 between the lightest and heaviest components in the same preparation.
An equal-mass split of 20mg each would deliver approximately 58.4 micromoles of KPV, 49.8 of GHK-Cu, 14.1 of BPC-157 and 4.0 of thymosin β4. KPV would outnumber thymosin β4 by roughly fifteen to one on a molar basis while being present at identical mass.
Those figures are illustrative, since the actual breakdown is unpublished. The conclusion holds regardless of the true ratio: any design reasoning from the 80mg label total, or from an assumed equal split, is reasoning about mass when the biology responds to moles.
How Does KLOW Peptide Compare With GLOW?
Same three peptides plus KPV, at a higher total fill. That is the whole difference on paper, and it has two practical consequences worth separating.
The first is mechanistic. Adding an NF-κB suppressor to a blend otherwise aimed at construction and mobility changes the character of the preparation. Whether that addition helps depends entirely on the research question, and in a model where inflammatory signalling is the variable under study, adding a compound that suppresses it may confound rather than assist.
The second is attributional. Three components already make an observed effect hard to assign. Four make it harder, and the number of possible pairwise interactions rises from three to six.
Anyone choosing between the two should ask whether the fourth component is part of the hypothesis or part of the noise. If the study concerns matrix and vasculature, GLOW isolates that better. If inflammatory modulation is genuinely in scope, KLOW is the more complete tool and the harder one to interpret.
What Controls Does a Four-Component Blend Need?
Single-component arms, and there is no shortcut. All four compounds are available separately, and a design running each alone alongside the blend is the only way to compare the combined effect against the sum of individual effects.
A copper control belongs in the design too. GHK-Cu carries copper(II) and the other three do not, so any copper-dependent effect will track with the GHK-Cu arm and can be mistaken for peptide activity. A copper salt at matched molar concentration separates the two, and it is routinely omitted.
Transporter competition is a fourth-component-specific consideration. KPV enters cells through PepT1, which carries a broad range of di- and tripeptides. Whether the presence of three other peptides affects KPV uptake through competition for that transporter is unstudied for this combination and is a plausible interaction rather than a remote one.
Order of addition is worth controlling where the assay permits. Adding components sequentially rather than as a premixed solution can produce different behaviour, particularly where transporter competition is in play.
What Does the Fourth Component Change Analytically?
Adding KPV to the KLOW peptide three-component base creates a specific analytical problem that the GLOW blend does not have.
The four KLOW peptide components span 342.43 to 4963.55 daltons, and they differ correspondingly in hydrophobicity and in chromatographic behaviour. KPV is small, polar and poorly retained on a reversed-phase column, eluting near the void volume where it is difficult to quantify. Thymosin β4 is large and retains strongly.
A single gradient that resolves all four adequately is harder to develop than one covering three. Methods optimised for the larger peptides typically lose KPV entirely, and laboratories quantifying a KLOW preparation sometimes report three components without noticing the fourth was never measured.
Hydrophilic interaction chromatography handles the small polar component well but performs poorly on the larger ones, so a complete composition analysis may require two methods rather than one.
The practical implication for anyone verifying a KLOW lot is to check what the certificate of analysis actually measured. A purity figure derived from a method that cannot see KPV describes three of four components.
What Should a Four-Component Certificate Show?
The analytical requirements scale with component count, and for four peptides spanning a fourteen-fold mass range the certificate needs to be specific about method as well as findings.
Component breakdown in milligrams is the baseline, and it should cover all four rather than three plus a remainder.
Method disclosure matters more here than for simpler products. A certificate stating that composition was determined by reversed-phase chromatography should also state whether the gradient resolved KPV, because many do not.
Copper content by elemental analysis covers the GHK-Cu stoichiometry, and individual purity per component covers what a blended figure would obscure.
Where a certificate reports a single purity number for the whole blend without naming the method or the components, it is describing something less useful than it appears.
Reconstitution and Storage in Laboratory Practice
Eighty milligrams is a substantial quantity spread across four compounds of very different sizes. Decide the reconstitution volume against the working range before opening, and record it immediately.
Add diluent slowly against the vial wall and swirl gently until the cake clears. Do not shake. Four components dissolving together means incomplete dissolution can leave one under-represented without any visible sign, so allow adequate time rather than rushing.
The copper component brings the usual requirements: protect from light, avoid chelating agents in downstream buffers, and treat colour loss as a degradation signal. Blue to blue-violet is the expected appearance.
Hold lyophilized material at -20°C sealed and dark, reconstituted solution at 2-8°C shielded from light and aliquoted before freezing. Record lot, diluent, volume, total concentration, date and storage location. With four components in one solution the record is the only route back to an explanation when something looks wrong.
The same blend is stocked as a KLOW peptide pen, a preloaded 3ml autoinjector at 80mg/ml. That format skips the reconstitution described here and fixes the concentration at manufacture, which removes one source of error and removes one degree of control at the same time. The preloaded autoinjector range covers that trade across seventeen products.
A Note on Comparing Against GLOW
Where a programme uses both blends, comparing them requires care that the shared naming discourages.
They differ in component count, total fill and, unavoidably, in the proportion each component contributes. A KLOW vial at 80mg containing four peptides delivers less of each individual component than an equal-mass GLOW split three ways would.
Any comparison therefore needs the component breakdown for both, converted to moles, before the two can be placed on the same axis. Comparing at matched total peptide mass compares two different molar compositions.
A bridging experiment running both at matched molar GHK-Cu concentration, the shared component present in largest quantity, is one practical way to anchor the comparison.
Published Literature
Validated against publisher records or primary indexes. Every entry covers a single component. No published study examines the four peptides together.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. FEBS Letters. 1988;238(2):343-346.
- Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520
- Hsieh MJ, Liu HT, Wang CN, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. Journal of Applied Physiology. 2011;110(3):774-780. PMID: 21030672
- Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. International Journal of Biochemistry and Cell Biology. 2001;33(3):205-220.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. Gastroenterology. 2008;134(1):166-178.
Frequently Asked Questions
What is KLOW peptide?
A lyophilized four-component research vial containing KPV, BPC-157, TB-500 and GHK-Cu at 80mg total. It is the three-peptide GLOW composition with KPV added. Supplied for laboratory research use only and not approved for human or veterinary use anywhere.
What does KPV contribute?
NF-kappa-B suppression. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, residues 11 to 13, and published work reports it enters cells through the PepT1 transporter and reduces NF-kappa-B activation. That is mechanistically distinct from the other three components.
How does KLOW differ from GLOW?
Same three peptides plus KPV, at a higher total fill. Mechanistically it adds an inflammatory-signalling suppressor to a blend otherwise aimed at matrix construction, vascular support and cell mobility. Attributionally it makes an observed effect harder to assign.
How wide is the molar spread?
Wider than any other product here. Molecular weights run from 342.43 for KPV to 4963.55 for thymosin beta 4, a factor of 14.5. An equal-mass split of 20mg each would give roughly 58.4, 49.8, 14.1 and 4.0 micromoles respectively.
Why does the molar spread matter?
Because biology responds to molar concentration rather than mass. Receptor occupancy, transporter kinetics and stoichiometric binding all scale with moles. A design reasoning from the 80mg label total, or from an assumed equal split, is reasoning about the wrong quantity.
What controls does this blend require?
Single-component arms for all four, run alongside the blend, since that is the only way to compare combined effect against the sum of parts. A copper salt control at matched molar concentration is also needed, because any copper-dependent effect will otherwise be attributed to the tripeptide.
Could the components interfere with each other?
Plausibly. KPV enters cells through PepT1, which carries a broad range of di- and tripeptides. Whether three other peptides present in the same solution compete for that transporter is unstudied for this combination, and it is a reasonable interaction to expect rather than a remote one.
When would GLOW be the better choice?
When the research question concerns matrix and vasculature specifically. Adding an NF-kappa-B suppressor to a model where inflammatory signalling is the variable under study may confound the readout rather than assist it. Three components also isolate better than four.
Why is dissolution time worth attention here?
Because four components dissolving together means incomplete dissolution can leave one under-represented with no visible sign. The findinging solution would differ from the label composition, and nothing about its appearance would indicate the problem. Allow adequate time rather than rushing.
What should be recorded?
Lot number, diluent identity and volume, preparation date, total concentration, storage conditions and location. With four components in one solution and no way to separate them afterward, contemporaneous records are the only route back to an explanation when a finding looks wrong.
What analytical problem does the fourth component create?
KPV is small and polar and retains poorly on reversed-phase columns, eluting near the void volume where quantification is difficult. Methods optimised for the larger components typically lose it entirely, so a certificate may report three components without noting the fourth was never measured.
Does one chromatographic method cover all four?
Rarely. The components span 342.43 to 4963.55 daltons with correspondingly different retention behaviour. Hydrophilic interaction chromatography handles the small polar component well and the larger ones poorly, so complete composition analysis may need two methods.
What should be checked on the certificate?
What the method actually measured. A purity figure derived from a gradient that cannot resolve KPV describes three of four components, and a buyer reading it as a whole-product figure is reading something the analysis does not support.
Compliance Statement
KLOW Blend 80mg is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
22 reviews for KLOW Blend (80mg)